Antibe Therapeutics Inc
TSX:ATE

Watchlist Manager
Antibe Therapeutics Inc Logo
Antibe Therapeutics Inc
TSX:ATE
Watchlist
Price: 0.295 CAD Market Closed
Market Cap: 4.7m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of ATE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-0.4
Industry
22.3
Forward
-0.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.5
Industry
17.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.5
Industry
23.8
More Details
0.2
P/B
P/B
Price to Book Value
0.2
vs History
vs Industry
Median 3Y
0.2
Median 5Y
0.2
Industry
2.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
More Details
1.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
1.2
vs History
vs Industry
Median 3Y
1.2
Median 5Y
1.2
Industry
13.3
Forward
1
More Details
1.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
1.2
vs History
vs Industry
Median 3Y
1.2
Median 5Y
1.2
Industry
16.8
Forward
1
More Details
1.3
EV/OCF
EV/OCF
Enterprise Value to OCF
1.3
vs History
vs Industry
Median 3Y
1.3
Median 5Y
1.3
Industry
15.6
More Details
1.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
1.3
vs History
vs Industry
Median 3Y
1.3
Median 5Y
1.3
Industry
18
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
Median 3Y
-0.8
Median 5Y
-0.8
Industry
2
More Details

Multiples Across Competitors

ATE Competitors Multiples
Antibe Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Antibe Therapeutics Inc
TSX:ATE
4.7m CAD 0 -0.3 1.2 1.2
US
Eli Lilly and Co
NYSE:LLY
723.3B USD 14.7 65.1 35 38.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
402.5B USD 4.4 17.8 13.5 17.8
CH
Roche Holding AG
SIX:ROG
204.5B CHF 3.4 24.7 9.3 10.9
UK
AstraZeneca PLC
LSE:AZN
172.2B GBP 4 27.4 112.5 168.2
CH
Novartis AG
SIX:NOVN
182.3B CHF 4.1 16.4 9.9 13.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.1 9.2 10.5
US
Merck & Co Inc
NYSE:MRK
199.6B USD 3.1 12.2 7.9 9.4
IE
Endo International PLC
LSE:0Y5F
183.8B USD 79.3 -62.9 292.4 733.2
US
Pfizer Inc
NYSE:PFE
133B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
CA
Antibe Therapeutics Inc
TSX:ATE
Average P/E: 24.2
Negative Multiple: -0.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
65.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.8
27%
0.7
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
27.4
36%
0.8
CH
Novartis AG
SIX:NOVN
16.4
16%
1
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
18%
0.7
US
Merck & Co Inc
NYSE:MRK
12.2
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.9 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Antibe Therapeutics Inc
TSX:ATE
Average EV/EBITDA: 394.9
1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.5
7%
1.9
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
112.5
10%
11.2
CH
Novartis AG
SIX:NOVN
9.9
5%
2
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
13%
0.7
US
Merck & Co Inc
NYSE:MRK
7.9
7%
1.1
IE
E
Endo International PLC
LSE:0Y5F
292.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Antibe Therapeutics Inc
TSX:ATE
Average EV/EBIT: 1 701.4
1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.8
13%
1.4
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
168.2
23%
7.3
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.4
10%
0.9
IE
E
Endo International PLC
LSE:0Y5F
733.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

See Also

Summary
ATE intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATE stock valuation using valuation multiples.
Wall Street Estimates
ATE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 271,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.